A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 50 |
| Updated: | 4/6/2019 |
| Start Date: | October 2015 |
| End Date: | January 2016 |
Effect of LY3314814 on the Pharmacokinetics of Dabigatran in Healthy Subjects
The purpose of this study is to learn about the effect of lanabecestat on how the body
absorbs and processes dabigatran etexilate and how dabigatran etexilate affects lanabecestat
when they are taken together. This study will last about 28 days and participants will be
asked to take an lanabecestat tablet daily for 19 days and a dabigatran etexilate tablet on 3
occasions. Screening is required within 30 days prior to the start of the study.
absorbs and processes dabigatran etexilate and how dabigatran etexilate affects lanabecestat
when they are taken together. This study will last about 28 days and participants will be
asked to take an lanabecestat tablet daily for 19 days and a dabigatran etexilate tablet on 3
occasions. Screening is required within 30 days prior to the start of the study.
Inclusion Criteria:
- Overtly healthy males and females
Exclusion Criteria:
- Eye abnormalities or disease
- History of vitiligo or any skin color disorder
- Have a history psychiatric or brain disease including seizures
- Have smoked within the last 3 months
- Are unwilling to avoid food and drinks containing grapefruit or Seville oranges for
the duration of the study
- Have known allergies to dabigatran etexilate and related compounds
We found this trial at
1
site
